Paid Clinical Trials Bellevue
Discover 647 paid clinical trials in Bellevue, Nebraska. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Sponsor:
Cytokinetics
Location:
Code:
NCT06412666
Conditions
Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Aficamten
Placebo
Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Sponsor:
North Texas Veterans Healthcare System
Location:
Code:
NCT02660866
Conditions
Peripheral Arterial Disease
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo + background APT + SMT
Vorapaxar 2.08 mg/d + background APT + SMT.
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Sponsor:
Genentech, Inc.
Location:
Code:
NCT05968326
Conditions
Adenocarcinoma, Pancreatic Ductal
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Autogene cevumeran
Atezolizumab
mFOLFIRINOX
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Sponsor:
RayzeBio, Inc.
Location:
Code:
NCT06590857
Conditions
Metastatic Breast Cancer
HER2-negative Breast Cancer
ER+ Breast Cancer
Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RYZ101
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Sponsor:
Boehringer Ingelheim
Location:
Code:
NCT06632457
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Survodutide
Placebo matching survodutide
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
US National OCS Liver Perfusion (OLP) RegistryUS National OCS Liver Perfusion (OLP) Registry
Sponsor:
TransMedics
Location:
Code:
NCT05940857
Conditions
Liver Transplant
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
OCS Liver
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Sponsor:
Bayer
Location:
Code:
NCT04464226
Conditions
Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Darolutamide (Nubeqa, BAY1841788)